{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-000267","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.907290+00:00","generated_at":"2026-05-16T11:44:06.499633+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Telomir-1 reduces tumor growth and metastases in aggressive TNBC models in preclinical study","bullets":["Telomir-1 showed statistically significant reductions in primary tumor growth in two of three aggressive TNBC zebrafish xenograft models.","In a paclitaxel-resistant model, Telomir-1 reduced tumor growth as monotherapy and in combination, and cut cancer cell spread.","Third model (broadly treatment-resistant, ~15-25% of TNBC) showed no significant effect from Telomir-1 or paclitaxel.","Responsive models represent ~40-60% of TNBC; company plans patient selection based on tumor biology for future trials.","Study used BioReperia’s ZTX ONCOLEADS platform; company continues IND-enabling activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-000267","json":"https://secwatch.observer/filing/0001493152-26-000267.json","markdown":"https://secwatch.observer/filing/0001493152-26-000267.md","text":"https://secwatch.observer/filing/0001493152-26-000267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226000267/0001493152-26-000267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226000267/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:44:06.499633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}